Sandoz announces new global initiative “Act4Biosimilars” to improve patient access and increase adoption by at least 30% in more than 30 countries by 2030

  • The multidisciplinary steering committee was created to drive action and includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders

  • The action plan will provide a roadmap and tools to improve the approval, accessibility, acceptability and affordability (4As) of biosimilars.

  • Sandoz launched an initiative to support improved healthcare access, equity and sustainability

Basel, May 31, 2022 – Sandoz, the global leader in generics and biosimilars, today announced the launch of a new global initiative called “Act4Biosimilars” to help tackle health inequality and inequality around the world. Act4Biosimilars aims to increase patient access to advanced drugs by facilitating greater approval, accessibility, acceptability and affordability (4a) of biosimilars. The initiative is supported by a multidisciplinary steering committee of patient advocacy leaders, healthcare professionals, biosimilars experts and industry leaders from around the world, with a mission to increase global adoption of biopharmaceuticals by at least 30% in more than 30 countries by 2030.

A biosimilar is a successor to a biological medicine (also known as a “reference medicine”) whose patent has expired and exclusivity rights have been lost. Biosimilars align with their respective reference medicine for quality, safety, and efficacy. Thus, the biosimilar can be expected to behave in the same way as the reference medicine in all indications and patient groups for which the reference medicine has been approved. Biosimilars are used in the treatment and prevention of many disabling and life-threatening diseases such as cancer, psoriasis, arthritis, and diabetes.

“As a result of their affordability, biosimilars have opened a new field of possibilities for patients by enabling biologic drugs to become more widely available to those who need these advanced life-changing therapies,” said Zorana Maravik, CEO of Gastrointestinal Cancer. Europe. “However, until we address current inequalities in access to biosimilars, far too many patients will continue to miss out on treatment with the best drug possible.”

Act4Biosimilars.com The 12 goals identified under the 4As are set by the Steering Committee to achieve the mission. These include ensuring fair pricing, involving patients in treatment decisions and simplifying the development of biosimilars.

As an immediate next step, the Steering Committee is developing an action plan to provide the strategies, tools, and activities needed to equip and empower stakeholders to achieve these 12 goals, across 30 countries and beyond. The Country Indicator Maps will support the action plan to track and measure the change that groups, associations and organizations are driving around the world.

Professor Emeritus Tori Kvin, former president, said: “While countries like Norway are leading the way in adopting biosimilars and have succeeded in generating significant savings in health care by increasing the availability of biosimilars, other countries are still stepping up and aspiring to reach their full potential.” Department of Rheumatology, Diakongmite Hospital for 25 years. Misinformation about the safety, efficacy and science of biosimilars continues to cause confusion and hinder its understanding. Through the Act4Biosimilars Action Plan, we will prioritize steps needed to help educate, inform and create better actions across all countries and regions.”

The Steering Committee will participate in the development of the action plan with a range of biosimilar experts and key stakeholders, including patient organizations, healthcare professionals, trade associations, think tanks, government agencies and professional associations.

Act4Biosimilars is supported by founding sponsor Sandoz, a pioneer and global leader in biosimilars, who developed and delivered the first biosimilar drug to patients 16 years ago.

“Healthcare systems are facing greater pressures than ever before, which can be attributed to costs associated with a growing and aging population, more people being diagnosed with chronic diseases and, more recently, a pandemic,” said Richard Signor, CEO. Sandoz. “Biosimilars are part of the solution to support a more sustainable healthcare system for all, and we are proud to be the founding sponsor of Act4Biosimilars, which will work to provide the most affordable treatment options for patients who need them.”

About Act4Biosimilars
Act4Biosimilars is a global initiative that aims to increase patients’ access to biologics by facilitating greater approval, accessibility, acceptability, and affordability of biosimilars. Act4Biosimilars leads a multidisciplinary steering committee of patient advocacy leaders, healthcare professionals, biosimilars experts and industry leaders from around the world, with a mission to increase global adoption of biosimilars by at least 30% in more than 30 countries by 2030. Act4Biosimilars strives to boost the movement The globalization of biosimilars by clearly aligning and directing work on biosimilar challenges, patient access and sustainable healthcare and with the support of our founding sponsor, Sandoz. For more information, I got Act4Biosimilars.com. Follow Act4Biosimilars on LinkedIn. Follow Act4Biosimilars on Twitter.

disclaimer
This press release contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by words such as “likely,” “could,” “will,” “plan,” “may,” “could” , “will,” “expect,” “expect,” “look forward,” “believe,” “committed,” “enquiry,” “pipeline,” “launch” or similar terms, or through explicit or implicit discussions regarding potential marketing endorsements, new indications or labeling of products under consideration or approval described in this press release, or in connection with possible future revenue from such products You should not place undue reliance on such statements. These forward-looking statements are based on our current beliefs and our expectations regarding future events, subject to significant known and unknown risks and uncertainties.If one or more of these risks or uncertainties materialize, or if underlying assumptions prove incorrect, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantee that the products The experimental or approved ones described in this press release will be offered or approved for sale or for any additional indications or labeling in any market, or at any particular time. There can be no guarantee that, if approved, these generic products or biosimilars will be approved for all indications listed on the reference product label. There can be no guarantee that such products will be commercially successful in the future. In particular, our expectations for these products could be influenced by, among other things, uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions, delays or government regulations in general; special prescribing preferences of clinicians and patients; competition in general, including potential approval of generic versions or additional biosimilars to these products; Global trends towards health care cost containment, including price pressures, government reimbursement pressures, payers and the general public, and requirements for increased pricing transparency; the results of litigation, including intellectual property disputes or other legal efforts to prevent Sandoz or limit the sale of its products; general political, economic and business conditions, including the impacts and efforts to mitigate epidemic diseases such as COVID-19; safety, quality, data integrity, or manufacturing issues; Potential or actual data security and data privacy breaches, disruptions to our IT systems, and other risks and factors noted in Novartis AG’s current Form 20-F registered with the SEC. Novartis provides the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or otherwise.

About Sandoz
Sandoz, a division of Novartis, is a global leader in generics and biosimilars. Our goal is to lead in outreach to patients by developing and commercializing new, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valuable generic drug company. Our extensive portfolio of high quality pharmaceuticals, covering all major therapeutic areas, accounted for 2020 sales of $9.6 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Signor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

# # #

Novartis Media Relations
Email: media.relations@novartis.com

Investor Relations at Novartis
Central Investor Relations Line: +41 61324 7944
Email: Investor.relations@novartis.com

Center

North Amarica

Sameer Shah

+41 61324 7944

Sloane Simpson

+1862778 5052

Nicole Zensley
Isabella Zink

+41 61324 3809
+41 61324 7188